Gene Therapy (GT) achieved remarkable results in treating monogenic diseases deemed incurable by conventional medicine.
Although successful clinical trials have demonstrated the feasibility of GT for hematological and skin genetic disorders, genotoxicity of the products is still a concern.
This webinar will provide an overview on the tools available to characterize retroviral-based gene therapy-skin products.
We will also discuss the importance and the new perspectives regarding the assessment of products safety.
Davide Scaglione, PhD Chief Technology Innovation Officer - IGA Technology Services
Michele Palamenghi, PhD at the Centre for Regenerative Medicine, University of Modena and Reggio Emilia.